GSK today confirmed that it will invest more than £500m in the UK across its manufacturing sites to increase production of key active ingredients for its pharmaceutical products and vaccines.
The company announced selection of Ulverston in Cumbria as the location for the first new GSK manufacturing facility to be built in the UK for almost 40 years.
- In total more than £500m of investment confirmed, creating up to 1,000 new jobs.
- Includes £100m investment for GSK manufacturing in Scotland.
– Sir Andrew Witty, Chief Executive, GSK
The introduction of the patent box has transformed the way in which we view the UK as a location for new investments, ensuring that the medicines of the future will not only be discovered, but can also continue to be made here in Britain. Consequently, we can confirm that we will build GSK’s first new UK factory for almost 40 years and that we will make other substantial capital investments in our British manufacturing base. In total, this will create up to 1,000 new jobs over the lifetime of the projects.
Investment will also be made at the company’s two manufacturing sites in Scotland at Montrose and Irvine. In total, it is anticipated these investments will create up to 1,000 new jobs over the lifetime of the projects.